Lista de obras -

A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants

scientific article published on 26 October 2016

A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes

artículo científico publicado en 2011

A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses

artículo científico publicado en 2012

An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development

artículo científico publicado en 2004

An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality

artículo científico publicado en 2014

Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States ⬇️

artículo científico publicado el 7 de febrero de 2012

Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016.

artículo científico publicado en 2017

Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.

artículo científico publicado en 2013

Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses

artículo científico publicado en 2015

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons

Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays

artículo científico publicado en 2010

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens

artículo científico publicado en 2013

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment

artículo científico publicado en 2013

Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

artículo científico publicado en 2014

Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection

artículo científico publicado en 2006

Comprehensive assessment of 2009 Pandemic Influenza a (H1N1) Virus Drug Susceptibility in vitro ⬇️

artículo científico publicado el 1 de enero de 2010

Correction: Okomo-Adhiambo, M. et al. Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. Viruses 2010, 2, 2269–2289.

artículo científico publicado en 2011

Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods

artículo científico publicado en 2020

Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing

artículo científico publicado en 2011

Detection of oseltamivir-resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test

artículo científico publicado en 2019

Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors

artículo científico publicado en 2005

Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice

artículo científico publicado en 2009

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir

artículo científico publicado en 2015

Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.

artículo científico publicado en 2016

Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection

artículo científico publicado en 2006

H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis

artículo científico publicado en 2010

Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins

artículo científico publicado en 2016

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

artículo científico publicado en 2009

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses

artículo científico publicado en 2010

Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor

artículo científico publicado en 2007

Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018

Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

artículo científico publicado en 2008

Molecular Characterizations of Surface Proteins Hemagglutinin and Neuraminidase from Recent H5Nx Avian Influenza Viruses.

artículo científico publicado en 2016

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART

artículo científico publicado en 2017

N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site

artículo científico publicado en 2010

Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective ⬇️

artículo científico publicado el 13 de octubre de 2010

Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses

artículo científico publicado en 2015

Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.

artículo científico publicado en 2009

Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model

artículo científico publicado en 2005

Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry

artículo científico publicado en 2017

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein ⬇️

artículo científico publicado el 16 de agosto de 2011

Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir

artículo científico publicado en 2020

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

artículo científico publicado en 2006

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors

artículo científico publicado en 2005

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1

scientific article published on 17 October 2019

The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses

artículo científico publicado en 2013

Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.

artículo científico publicado en 2008

Lista de obras de

A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants

A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes

A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses

An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development

An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality

Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States ⬇️

Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016.

Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.

Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons

Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment

Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection

Comprehensive assessment of 2009 Pandemic Influenza a (H1N1) Virus Drug Susceptibility in vitro ⬇️

Correction: Okomo-Adhiambo, M. et al. Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. Viruses 2010, 2, 2269–2289.

Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods

Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing

Detection of oseltamivir-resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test

Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors

Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir

Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.

Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection

H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis

Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses

Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor

Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018

Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

Molecular Characterizations of Surface Proteins Hemagglutinin and Neuraminidase from Recent H5Nx Avian Influenza Viruses.

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART

N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site

Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective ⬇️

Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses

Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.

Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model

Quantification of Influenza Neuraminidase Activity by Ultra-High Performance Liquid Chromatography and Isotope Dilution Mass Spectrometry

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein ⬇️

Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1

The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses

Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.